141 related articles for article (PubMed ID: 30362418)
1. CDK9 as an Appealing Target for Therapeutic Interventions.
Eyvazi S; Hejazi MS; Kahroba H; Abasi M; Zamiri RE; Tarhriz V
Curr Drug Targets; 2019; 20(4):453-464. PubMed ID: 30362418
[TBL] [Abstract][Full Text] [Related]
2. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
3. CDK9 inhibition strategy defines distinct sets of target genes.
Garriga J; Graña X
BMC Res Notes; 2014 May; 7():301. PubMed ID: 24886624
[TBL] [Abstract][Full Text] [Related]
4. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
5. The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.
Paparidis NF; Durvale MC; Canduri F
Mol Biosyst; 2017 Jan; 13(2):246-276. PubMed ID: 27833949
[TBL] [Abstract][Full Text] [Related]
6. The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies.
Rice AP
Curr Pharm Des; 2017; 23(28):4098-4102. PubMed ID: 28677507
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29.
Zhou M; Huang K; Jung KJ; Cho WK; Klase Z; Kashanchi F; Pise-Masison CA; Brady JN
J Virol; 2009 Jan; 83(2):1036-44. PubMed ID: 18971272
[TBL] [Abstract][Full Text] [Related]
8. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcription.
Ou M; Sandri-Goldin RM
PLoS One; 2013; 8(10):e79007. PubMed ID: 24205359
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological targeting of CDK9 in cardiac hypertrophy.
Krystof V; Chamrád I; Jorda R; Kohoutek J
Med Res Rev; 2010 Jul; 30(4):646-66. PubMed ID: 19757441
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms controlling CDK9 activity.
Marshall RM; Grana X
Front Biosci; 2006 Sep; 11():2598-613. PubMed ID: 16720337
[TBL] [Abstract][Full Text] [Related]
12. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
14. Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy.
Karati D; Mahadik KSR; Trivedi P; Kumar D
Anticancer Agents Med Chem; 2023; 23(4):383-403. PubMed ID: 35708082
[TBL] [Abstract][Full Text] [Related]
15. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases.
Romano G; Giordano A
Cell Cycle; 2008 Dec; 7(23):3664-8. PubMed ID: 19029809
[TBL] [Abstract][Full Text] [Related]
16. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ; Welsh SA; Devlin JR; Barbieri E; Knight DA; Offley S; Bjelosevic S; Costacurta M; Todorovski I; Kearney CJ; Sandow JJ; Fan Z; Blyth B; McLeod V; Vissers JHA; Pavic K; Martin BP; Gregory G; Demosthenous E; Zethoven M; Kong IY; Hawkins ED; Hogg SJ; Kelly MJ; Newbold A; Simpson KJ; Kauko O; Harvey KF; Ohlmeyer M; Westermarck J; Gray N; Gardini A; Johnstone RW
Cell; 2021 Jun; 184(12):3143-3162.e32. PubMed ID: 34004147
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Cdk9 T-loop phosphorylation in resting and activated CD4(+) T lymphocytes.
Ramakrishnan R; Dow EC; Rice AP
J Leukoc Biol; 2009 Dec; 86(6):1345-50. PubMed ID: 19741158
[TBL] [Abstract][Full Text] [Related]
18. CDK9 inhibitors in acute myeloid leukemia.
Boffo S; Damato A; Alfano L; Giordano A
J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9.
Itkonen HM; Poulose N; Steele RE; Martin SES; Levine ZG; Duveau DY; Carelli R; Singh R; Urbanucci A; Loda M; Thomas CJ; Mills IG; Walker S
Mol Cancer Res; 2020 Oct; 18(10):1512-1521. PubMed ID: 32611550
[TBL] [Abstract][Full Text] [Related]
20. Cellular control of gene expression by T-type cyclin/CDK9 complexes.
Garriga J; Graña X
Gene; 2004 Aug; 337():15-23. PubMed ID: 15276198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
